CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35+0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Maintain Nasdaq listing compliance: Market Value $0.0M vs $35M target.
CytoSorbents aims to reach operating cash flow breakeven in the second half of 2026. Operating cash flow improved from negative $4.8M in 2025-Q4 to negative $1.2M in 2026-Q1. Analysts expect revenue growth of about 17% next year. The stock trades cheaply versus peers with a price far below consensus estimates.
The company is loss-making with negative cash flow and net income. It faces delisting risks from Nasdaq. Recent earnings missed expectations and the stock has sold off sharply. Achieving cash flow breakeven may be delayed or fail.
The market prices in about 17% revenue growth and a turnaround to breakeven cash flow. Our fair value near $2.61 reflects these expectations. The recent sharp selloff and regulatory risks suggest the market doubts the turnaround's durability.
Breaks if: Company is delisted or transferred from Nasdaq
Breaks if: operating cash flow remains negative through H2 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on returning to profitable growth. The current thesis state suggests cautious optimism as management works toward key operational goals while facing significant risks.
The market appears to have priced in a low expectations gap, indicating that investors are not overly optimistic about immediate performance. Valuation is considered cheap compared to peers, but the fundamentals are currently under pressure.
Management is on track to achieve operating cash flow breakeven in the second half of 2026, with some improvement in revenue and gross margins. However, the company has faced challenges, including recent earnings misses and regulatory issues, which add to the uncertainty.
The long-term thesis hinges on the company's ability to meet its operational goals, especially achieving FDA approval for DrugSorb-ATR and returning the CytoSorb business to sustainable growth. Additionally, external factors like sector performance and economic conditions will play a crucial role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company posted a modest revenue beat for Q2 2026. This indicates growth in key clinical applications, which supports the thesis. There are no new threats affecting the outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Complete strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash flow breakeven in the second half of 2026.
Stated as a priority in 5 of last 5 quarters. Revenue grew from $8.9M in 2026-Q1 to $9.6M in 2026-Q2, operating loss improved from -$3.0M to -$2.6M, and gross margin increased from 69% to 73%. Management has consistently reiterated the goal of achieving operating cash flow breakeven in the second half of 2026, and the financial trajectory shows delivering progress toward this milestone.
“We continue to expect cash flow break even in the 2H of 2026.”
“We believe we remain on track toward our objective of achieving operating cash flow breakeven in the second half of this year.”
“We now expect to be operating cash flow break even in the second half of 2026.”
“We believe these actions will continue to drive improvements to support our goal of achieving operating cash flow breakeven in the second half of this year.”
“We now anticipate achieving cash flow breakeven in the second half of 2026.”
Breaks if: revenue growth falls below 10% in FY26
In the next 1-3 years, CTSO's performance will depend on management's execution of its strategic priorities and the overall healthcare market environment. Not investment advice.